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Abstract
FXS is the most common genetic cause of intellectual (ID) and autism spectrum disorders (ASD). FXS is caused by
loss of FMRP, an RNA-binding protein involved in the translational regulation of a large number of neuronal
mRNAs. Absence of FMRP has been shown to lead to elevated protein synthesis and is thought to be a major
cause of the synaptic plasticity and behavioural deficits in FXS. The increase in protein synthesis results in part from
abnormal activation of key protein translation pathways downstream of ERK1/2 and mTOR signalling.
Pharmacological and genetic interventions that attenuate hyperactivation of these pathways can normalize levels of
protein synthesis and improve phenotypic outcomes in animal models of FXS. Several efforts are currently
underway to trial this strategy in patients with FXS. To date, elevated global protein synthesis as a result of FMRP
loss has not been validated in the context of human neurons. Here, using an isogenic human stem cell-based
model, we show that de novo protein synthesis is elevated in FMRP-deficient neural cells. We further show that this
increase is associated with elevated ERK1/2 and Akt signalling and can be rescued by metformin treatment. Finally,
we examined the effect of normalizing protein synthesis on phenotypic abnormalities in FMRP-deficient neural
cells. We find that treatment with metformin attenuates the increase in proliferation of FMRP-deficient neural
progenitor cells but not the neuronal deficits in neurite outgrowth. The elevated level of protein synthesis and the
normalization of neural progenitor proliferation by metformin treatment were validated in additional control and
FXS patient-derived hiPSC lines. Overall, our results validate that loss of FMRP results in elevated de novo protein
synthesis in human neurons and suggest that approaches targeting this abnormality are likely to be of partial
therapeutic benefit in FXS.
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Introduction
Fragile X syndrome (FXS) is the leading genetic cause of
intellectual (ID) and autism spectrum disorders (ASD)
[1]. The disease is caused by the expansion of a CGG tri-
nucleotide repeat tract in the promoter region of FMR1
leading to epigenetic silencing and loss of its protein
product, FMRP [2]. Individuals with FXS present with
hypersensitivity, anxiety, epilepsy and cognitive prob-
lems. In addition, FXS patients exhibit characteristic
physical features that include long face, prominent ears
and macro-orchidism [3].
FMRP is a brain-enriched RNA-binding protein in-
volved in the translational regulation of a large number
of mRNAs that encode genes involved in neuronal
development and function [4, 5]. It is localized in the
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: utami@pouladilab.org; map@pouladilab.org
1Translational Laboratory in Genetic Medicine, Agency for Science,
Technology and Research, Singapore (A*STAR), 8A Biomedical Grove,
Immunos, Level 5, Singapore 138648, Singapore
Full list of author information is available at the end of the article
Utami et al. Molecular Autism           (2020) 11:41 
https://doi.org/10.1186/s13229-020-00350-5
somatodendritic compartment of neurons where it
represses the translation of target mRNAs by stalling the
ribosomes. Upon activation of translation initiation
factor signals, FMRP-mediated repression is abolished to
promote newly synthesized proteins that are required for
a myriad of cellular and neuronal functions including
synaptic plasticity [5]. Studies in Fmr1 knockout (KO)
mice have shown that absence of FMRP leads to abnor-
mal signalling of cell-surface receptor pathways, of
which metabotropic glutamate receptor 5 (mGluR5) has
been the most widely studied. This in turn results in an
elevation of global protein synthesis that has been
observed in multiple brain regions of FXS animal models
[6, 7]. mGluR receptors activate the phophoinositide-3-
kinase-Akt signalling to mechanistic target of Rapamycin
complex 1 (mTORC1) and/or Ras-Raf activation leading
to a hyper-sensitized extracellular signal regulated kinase
1/2 (ERK1/2) pathway. The increase in global protein
synthesis results in part from abnormal activation of key
protein translation pathways downstream of ERK1/2 and
mTORC1 signalling. Both signalling pathways converge
to activate components of the eukaryotic cap-dependent
translation machinery [8, 9]. Pharmacological and
genetic approaches that attenuate hyperactivation of
these pathways can normalize levels of protein synthesis
and have been shown to improve phenotypic outcomes
in animal models of FXS. These include several mGluR5
antagonists, GABA agonists, statins, lithium and riboso-
mal protein tyrosine kinase S6 (S6K) inhibitors [8, 10–
13].
Several therapeutic strategies are currently being eval-
uated in clinical trials for FXS, including treatments
aimed at normalizing protein synthesis. Altered protein
synthesis has been previously examined directly in FXS
lymphoblastoid cell lines and fibroblasts and indirectly
in FXS patients using positron-emission tomography [6,
14–16]. However, assessment in human neural cells, the
cell types of most relevance to neurodevelopmental and
neurological manifestations of FXS, remains lacking. The
aim of this study is to evaluate the protein synthesis sta-
tus and the effect of its normalization on phenotypic
deficits in human FMRP-deficient neural cells derived
from an isogenic human stem cell-based model.
Materials and methods
Cell culture
The cell lines used in this study are H1/WA01 hESC
(WiCell, Wisconsin) and isogenic FMR1KO hESC lines
generated by CRISPR/Cas9 targeting exon 3 of FMR1
gene in the H1 hESC line. Details of the generation of
FMR1KO hESC lines are described in Utami et al., BioR-
xiv 2019 [17]. Two control (HEL11.4 and HEL23.3) and
two FXS (HEL69.5 and HEL70.3) human-induced pluri-
potent stem cells (hiPSCs) were included for further
assessment of the protein synthesis phenotypes and met-
formin treatment effects [18].
Neural differentiation
hESCs were induced into neural progenitor cells (NPCs)
according to a previously published protocol [19].
Briefly, single-cell dissociated hESC at a density of 30,
000 cells/cm2 was plated in neural induction media
(NIM, DMEM/F12:NeuroBasal media 1:1 with 1% N2,
2% B27, 1% PenStrep, 1% GlutaMax, 10 ng/ml hLIF and
5 μg/ml Bovine Serum Albumin) containing 4 μM
CHIR99021 (Tocris), 3 μM SB431542 (Sigma) and
0.1 μM Compound E (Millipore) for the first 7 days. The
culture was then split at a 1:3 ratio for the next five pas-
sages using Accutase in NIM without Compound E on
Matrigel-coated plates.
For neuronal differentiation, NPCs were plated at a
density of 20,000 cells/cm2 on 50 μg/ml poly-L-
ornithine/10 μg/ml laminin-coated plates and grown in
NeuroDiff media (DMEM/F12/Neurobasal media (1:1)
supplemented with 1% N2, 2% B27, 20 ng/ml GDNF
(R&D Systems), 20 ng/ml BDNF (R&D Systems), 300 μM
dibutyryl-cyclic AMP (D0260, Sigma Aldrich) and 200
nM L-Ascorbic Acid (A4403, Sigma Aldrich)) for at least
3 weeks. Medium was changed every 2–3 days.
Metformin treatment
NPCs or neurons were seeded on Matrigel-coated plates
or poly-l-ornithine/laminin-coated plates, respectively at
a confluency of 30–40%. One day after plating, metfor-
min was added into the media at the concentration be-
ing evaluated. For the SUnSET protein synthesis assay,
metformin was added during the puromycin incubation.
For NPCs experiments, metformin was added to NPC
cultured between passage 5 and 7, and media with
metformin was refreshed daily for 3 days. In neurons,
metformin treatment was given for ~ 7 days, and media
with fresh metformin was changed every 2 days.
Immunofluorescence staining
Cells were plated on ethanol-treated coverslips and fixed
with 4% formaldehyde in phosphate buffer saline (PBS)
for 15 min at room temperature. After washing with
Tris-Buffered Saline (TBS), cells were incubated in
blocking buffer (TBS containing 5% goat serum, 1%
Bovine Serum Albumin and 0.1% Triton-X-100 (Sigma
Aldrich)) for 45 min at room temperature. Primary anti-
bodies were incubated with fixed cells overnight at 4 °C
in blocking buffer without Triton-X-100. The following
primary antibodies were used: anti-MAP2 rabbit poly-
clonal (AB5622, EMD Millipore), anti-TUJ1 mouse
monoclonal (MAB1637, Merck-Millipore), anti-Nestin
mouse monoclonal (MAB5326, Merck-Millipore), anti-
rat BrdU (sc-56258, Santa Cruz) and anti-Ki67 mouse
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monoclonal (MAB4190, Merck-Millipore). Cells were
subsequently stained with secondary antibodies conju-
gated to Alexa Fluor 555 or 488 (Molecular Probes,
Thermo Fisher) for 1 h at room temperature in the dark
and incubated with 1 μg/ml 4′,6-diamidino-2-phenylin-
dole (DAPI, Sigma Aldrich) for 10 min. Images were
captured using an FV1000 Inverted Confocal System.
Cell proliferation assay
Approximately 70% confluent NPCs were treated with
50 μM BrdU for 6 h, followed by fixation with 4% for-
maldehyde for 15 min at room temperature. For antigen
retrieval, coverslips were incubated serially three times
in ice-cold 1 N HCl for 10 min, 2 N HCl for 10 min at
room temperature, 2 N HCl for 20 min at 37 °C and
lastly in 1M borate buffer for 10 min. Immunofluores-
cence staining and imaging was performed as described
in the “Immunofluorescence staining” section using anti-
BrdU (sc56258, Santa Cruz) and anti-Ki67 (MAB4190,
Millipore) antibodies. To determine the proportion of
positive cells, images were captured from at least 10 ran-
domly selected areas. Quantification for each sample/
genotype was performed blinded from 3 coverslips per
genotype/treatment. The ImageJ software was then used
to compute the total number of cells (DAPI-stained nu-
clei) and the number of cells expressing the markers
using the CellCounter Plugin. Percentage of BrdU and
Ki67-positive cells was calculated from the ratio of
BrdU/Ki67+ cells over a total number DAPI.
De novo protein synthesis assay
De novo protein synthesis was measured using a previ-
ously described assay [20]. Cells were deprived of serum
for 16 h and after 4 h of recovery in complete medium
supplemented with 10% FBS, were treated with puro-
mycin (5 μg/ml) for 30 min. Pre-treatment with the
translation inhibitor cycloheximide (50 μM) for 15 min
was used to as a control to confirm specificity of the
assay. Following puromycin treatment, cells were incu-
bated with fresh medium for 15 min then washed with
ice-cold PBS and lysed directly in RIPA buffer, supple-
mented with cOmplete Protease Inhibitor (Roche). Sam-
ples were analysed by immunoblot, and puromycin
incorporation was detected using the mouse monoclonal
antibody PMY-2A4 (DSHB). Calnexin was used as load-
ing control.
Immunoblotting
Cells were lysed with RIPA buffer (Sigma Aldrich) con-
taining cOmplete Protease Inhibitor cocktail tablets
(Roche). Protein concentration was measured using the
Bradford assay (BioRad). The samples were denatured at
70 °C for 10 min in 4× NuPAGE sample buffer and 10×
NuPAGE reducing agent (Thermo Fisher). A total of
30 μg of protein per sample was separated on 12% Acryl-
amide FastCast kit (Bio-Rad) at 100 V for 3 h followed
by transfer to nitrocellulose membrane at 120 V for 1.5 h
at room temperature. The following primary antibodies
were used for detection: anti-FMRP (MAB2160, Milli-
pore; 6B8, Biolegend), anti-puromycin (DSHB, PMY2A4)
and anti-Calnexin (Sigma, C7431). Alexa-Fluor 680 goat
anti-mouse (Thermo Fisher) and DyLight 800 goat anti-
rabbit (Rockland) were used as secondary antibodies.
Membranes were imaged using the Li-Cor Odyssey in-
frared imaging system.
Neurite outgrowth measurements
To assess neurite outgrowth, NPCs were plated at a
density of 15,000 cells/cm2 in NeuroDiff media with
modifications (substituting N2 with CultureOne supple-
ment (Thermo Fisher)). The plate was imaged using an
IncuCyte Zoom Imaging system (Essen Bioscience, Ann
Arbor, MI) every 2 h for 7 days. Live-capture measure-
ments were performed in 9 image field per well, n = 4
per genotype per treatment condition. For metformin
treatment, metformin was added at day 1 post plating,
and media with/without metformin was changed every
2–3 days. Cells were imaged under phase contrast, and
analysis was performed using IncuCyte’s NeuroTrack
module. The neurite-calling algorithm automatically
traces the neurites from each cell body and masks the
neurites for the entire image field, with no pre-selection
of evaluated neurons. The growth rate of neurites in
each well was obtained by measuring the surface area
covered by neurites and expressed as mm/mm2.
Statistical analysis
All statistical analysis was carried out in GraphPad Prism
v7 (La Jolla, CA, USA). Statistical significance was ascer-
tained by one- or two-way ANOVA with appropriate post
hoc testing or by unpaired Student’s t test. Differences
were considered statistically significant when p < 0.05.
Results
Transcriptome profiling analysis reveals dysregulation of
protein synthesis-related pathways in FMRP-deficient
neural cells
We previously reported transcriptome-wide profiling in
FMR1 knockout isogenic neurons derived from H1 hu-
man embryonic stem cells (hESCs) to identify key mo-
lecular signatures associated with neurodevelopmental
deficits in FXS [17]. By using a focused meta-analysis of
a neuronal transcriptome dataset, we found that many of
the gene ontology (GO) categories associated with genes
upregulated in FMRP-deficient neurons are significantly
enriched in protein synthesis-related GO terms (Fig. 1a).
Examinations of the genes associated within these
categories, eIF-related genes, including eIF4A1, eIF4E,
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eIF4G1, eIF1B and eIF2A, were shown to be significantly
upregulated in the FMR1KO neurons (Fig. 1b). We
validated changes in four out of five EIF-related genes,
namely 4EBP1, EIF3J, EIF4A1 and EIF4H, in the
FMR1KO neurons by quantitative RT-PCR (Fig. 1c).
These data suggest that absence of FMRP may perturb
translation initiation processes in human neurons, con-
sistent with prior studies showing that FMRP regulates
initiation of translation by interacting with cap-binding
translation factor eIF4E and cytoplasmic FMRP-
interacting protein 1 (CYFIP1) [21].
De novo protein synthesis is elevated in FMRP-deficient
neural cells
To examine the basal rate of de novo protein synthesis
in FMRP-deficient neural cells, we differentiated isogenic
FMR1KO hESCs that were derived by CRISPR/Cas9-me-
diated disruption of FMR1 in H1 hESCs into neural
progenitor cells (NPCs) using a previously described
protocol [19] (Fig. 2a). FMR1KO NPCs expressed a simi-
lar level of the NPC markers Nestin and Pax6 as the iso-
genic control NPCs, as shown by immunofluorescence
and quantification of PAX6+ and NESTIN+ cells (Fig.
2b). We next performed the SUnSET assay of global
protein synthesis based on puromycin incorporation, an
efficient and reliable method to measure relative rates of
de novo protein synthesis [20]. We observed a significant
increase in the total level of de novo protein synthesis
based on elevated puromycin incorporation in the
FMRP-deficient lines compared to control (Fig. 2c).
There were no obvious differences in puromycin levels
between the cell lines following treatment with cyclohex-
imide (CHX), a potent blocker of mRNA translation,
confirming that the puromycin measurements accurately
reflect global levels of de novo protein synthesis.
To test whether FMRP-deficient neurons also exhibit
this elevation in global protein synthesis, we differenti-
ated NPCs into neurons as previously described [22]
(Fig. 2d). The cells differentiated from the FMR1KO,
and isogenic control lines expressed the neuronal
markers MAP2 and TUJ1 (Fig. 2e). Analysis of protein
synthesis using the SUnSET assay showed significantly
elevated de novo protein synthesis in FMRP-deficient
neurons compared to control neurons (Fig. 2f). Absence
of FMRP in FMR1KO cells in NPCs and neurons was
confirmed by immunoblotting (Fig. S1).
Increased Akt and ERK1/2 activation in FMRP-deficient
neural cells
Previous studies using Fmr1KO mice have shown that
increased global protein synthesis is associated with
activation of the MAPK/ERK1/2 and PI3K-Akt-mTOR
pathways [8, 9]. These pathways are associated with the
initiation of the 5′ cap-dependent translation of mRNAs.
ERK1/2 activates the MAPK-interacting kinase (Mnk),
thereby phosphorylating the eukaryotic initiation factor
Fig. 1 Transcriptome profiling analysis reveals dysregulation of protein translation-related pathways in FMRP-deficient neurons. a Functional
annotation of transcripts differentially expressed in FMR1KO neurons shows enrichment of protein-related synthesis pathways. b Heatmap of
representative differentially expressed genes related to protein translation in neurons. c Quantitative RT-PCR analysis for validation of changes for
a subset of EIF-related genes in control and FMR1KO neurons
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Fig. 2 Elevated protein synthesis, p-Akt and p-ERK levels in FMRP-deficient neural progenitors and neurons. a Schematic overview of
differentiation protocol to derive homogeneous population of NPCs using rapid neural induction protocol. b Control and FMR1KO hESC-derived
NPCs showing comparable level of NPCs markers expression, Nestin and Pax6. The number of positive cells for PAX6 and NESTIN was quantified
over the total number of cells (stained with DAPI). Scale bar = 25 μm. c Basal protein synthesis was determined in control and FMR1KO NPCs
using the SUnSET assay, showing significant elevation of protein synthesis in FMR1KO NPCs compared to control (CON). Values shown as mean ±
SEM based on n = 3 replicates per genotype; *p < 0.05 compared with control was determined by two-tailed unpaired Student’s t-test.
Puromycin labelling was performed in NPCs for 30 min, after which equal amounts of protein were loaded on the gel for immunoblot analysis
with anti-puromycin antibody. As a control, cycloheximide (CHX) was added to the cells and incubated for 15 min prior to Puro labelling. d
Schematic overview of differentiation protocol to differentiate NPCs into neurons. e Control and FMR1KO neurons express post-mitotic neuronal
markers, MAP2 and TUJ1. Scale bar = 25 μm. f Basal protein synthesis was assayed in neurons by SUnSET method, showing significantly elevated
level of puromycin expression in FMR1KO compared to the control. Values shown as mean ± SEM based on n = 3 replicates per genotype; *p <
0.05 compared with control was determined by two-tailed unpaired Student’s t-test. g The levels of phosphorylated Akt, total Akt,
phosphorylated ERK and total ERK in NPCs were determined by immunoblot. Protein loading was determined by the level of Calnexin.
Representative immunoblot was shown for each sample. Quantification of protein level was performed by ImageJ. Values shown as mean ± SEM
based on n = 3 replicates per genotype; *p < 0.05, **p < 0.01 compared with control was determined by unpaired Student’s t-test. h The levels
of phosphorylated Akt, total Akt, phosphorylated ERK and total ERK in neurons were determined by immunoblot. Protein loading was determined
by the level of Calnexin. Representative immunoblot was shown for each sample. Quantification of protein level was performed by ImageJ. Values
shown as mean ± SEM based on n = 3 replicates per genotype; *p < 0.05, **p < 0.01 compared with control was determined by unpaired
Student’s t-test
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4E (eIF4E) [21]. mTOR is activated by Akt, leading to
phosphorylation of eIF4E binding proteins (4EBPs),
which activates Eif4E. mTOR also initiate translation of
5′ TOP mRNA, which is linked to the activation of ribo-
somal protein S6 kinases (p70S6K) [9, 12]. To determine
whether parts of these pathways were affected, we exam-
ined the phosphorylation states of ERK and Akt. We ob-
served significant elevation in both phosphorylated Akt
and ERK level in the FMR1KO NPCs (Fig. 2g) and neu-
rons (Fig. 2h).
Metformin treatment normalizes protein synthesis in
FMRP-deficient neural cells in an ERK1/2- and Akt-
independent manner
Metformin, a first-line therapy for type 2 diabetes, has
recently been shown to normalize protein synthesis and
rescue core phenotypes of Fmr1KO mice [23]. To test
whether metformin treatment would alleviate the ele-
vated protein synthesis in human FMRP-deficient neural
cells, we treated FMR1KO neurons with metformin for
72 h and assessed the level of global protein synthesis
using the SUnSET assay. We found that treatment with
0.5 mM of metformin, a dose previously used in dermal
fibroblast cells and hepatocytes [24, 25], normalized the
elevated protein synthesis in FMR1KO neurons (Fig. 3a).
In addition, we tested the phosphorylation states of Akt
and ERK1/2 and found that they were not normalized in
the metformin-treated FMRP-deficient neurons (Fig. 3b).
Similar results were obtained in NPCs where treatment
with 0.5 mM of metformin normalized the elevation in
protein synthesis but not the phosphorylation states of
Akt or ERK1/2 (Figure S2A-B). We further tested two
additional doses of metformin in NPCs (0.1 and 1mM)
and found that the higher (1 mM), but nor lower (0.1
mM) dose, normalized global protein synthesis but did
not affect phosphorylated Akt/ERK1/2 levels in
FMR1KO NPCs (Figure S3A,B). These results suggest
that metformin’s effects on protein synthesis are, at least
at the doses used here, independent of Akt/ERK1/2
pathway modulation.
Normalization of protein synthesis ameliorates the
increased proliferation in FMRP-deficient neural cells
Increased proliferation has been observed in multiple
FXS iPSC- and hESC-derived neural lines [26–28]. To
test whether metformin treatment and the associated
normalization of elevated protein synthesis can rescue
phenotypic abnormalities caused by FMRP deficiency,
we examined the proliferation status of FMRP-deficient
NPCs. We treated NPCs with a range of doses of met-
formin (0.25, 0.5 and 1mM) for 3 days and evaluated the
number NPCs immunopositive for Ki67 and BrdU, two
markers of cell proliferation (Fig. 4a). While the vehicle-
treated FMR1KO NPCs were significantly more
proliferative than control NPCs, the elevated prolifera-
tion rate in the FMR1KO NPCs was significantly rescued
upon metformin treatment for all doses (Fig. 4b). How-
ever, we noted that the number of proliferating cells in
the highest dose (1 mM) was significantly reduced for
both control and FMR1KO cells, which is consistent
with the known properties of metformin and its effect
on proliferation of various type of cells [29–31]. Metfor-
min treatment had no significant effect on the total
number control or FMR1KO NPCs for duration tests
(Fig. S4).
Validation of excessive protein synthesis and metformin
treatment effect in additional FXS hiPSC lines
To evaluate whether the excessive protein synthesis
phenotype observed in the isogenic FMR1KO and con-
trol cells can be observed in patient derived cells, we
performed the SUnSET assay in two additional control
and FXS hiPSC-derived NPCs. We indeed observed ele-
vated level of puromycin incorporation in FXS hiPSC-
derived NPCs compared to controls (Fig. S5A). In
addition, we observed a significantly increased prolifera-
tion rate in the FXS hiPSC-derived NPCs as measured
by Ki67- and BrdU-positive cells (Fig. S5B,C). Similar to
the isogenic FMR1KO lines, treatment with 0.5 mM of
metformin normalized the proliferation rate of FXS
hiPSC-derived NPCs to control levels (Fig. S5C).
Normalization of protein synthesis does not improve
neurite outgrowth defects in FMRP-deficient neurons
Neurite outgrowth has been shown to be affected in FXS
hiPSC- and hESCs-derived neurons [32–34]. We have
shown previously by using longitudinal neurite tracing
that FMR1KO neurons have reduced neurite outgrowth
compared to the control [17]. To examine whether res-
toration of protein synthesis corrects this neurodevelop-
mental abnormalities, we treated FMRP-deficient
neurons with 0.5 mM and 1mM metformin and assessed
neurite outgrowth (Fig. 4c). Metformin treatment did
not rescue the neurite outgrowth and branching deficits
suggesting that alleviation of excessive protein synthesis
may not be sufficient to correct all FMRP deficiency-
related abnormalities such as neurite outgrowth deficits.
Discussion
Effective therapies that address the core symptoms of
FXS remain lacking. Therapeutic efforts to date have
largely focused on normalizing synaptic plasticity deficits
in FXS mouse models by targeting key receptors that
regulate FMRP signalling [10, 11, 13, 15, 35]. While
drugs manipulating these major receptors such as
mGluR5 have shown very promising results in animal
models, they have failed to meet their primary endpoints
in clinical trials [36–39]. Though the reasons for this
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apparent lack of translatability of therapeutic success
from animal models to the clinic are a subject of debate,
the disappointing outcome has highlighted the need and
the added-value of validating candidate therapies in the
context of human physiology. In this study, we
demonstrate that global protein synthesis, a current tar-
get of therapeutic efforts, is elevated in FMRP-deficient
human neural cells. We further demonstrate that met-
formin, a candidate therapy presently in clinical trials,
normalizes elevated protein synthesis and rescues some,
Fig. 3 Metformin corrects the aberrantly elevated protein synthesis in FMRP-deficient neurons but does not normalize the phosphorylated levels
of Akt and ERK. a Global protein synthesis was determined by SUnSET assay, and representative immunoblot image was shown. Metformin (0.5
mM) was added to the neurons for 72 h followed by puromycin incorporation for 30 min. Protein loading was determined by the level of
Calnexin. Representative immunoblot image was shown, and relative puromycin expression was quantified by ImageJ. Values shown as mean ±
SEM from three biological replicates per sample. Statistical significance was shown as *p < 0.05, **p < 0.01, as determined by one-way ANOVA. b
Expressions of phosphorylated Akt, total Akt, phosphorylated ERK and total ERK for untreated and metformin-treated condition were assessed by
immunoblot. Protein loading was determined by the level of Calnexin. Phosphorylated Akt/total Akt and phosphorylated ERK/total ERK were
quantified by ImageJ. Values shown as mean ± SEM from three biological replicates per sample. Statistical significance was shown as *p < 0/05,
**p < 0.01, as determined by one-way ANOVA
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but not all, neurodevelopmental abnormalities caused by
FMRP deficiency in human neural cells.
Analysis of protein synthesis in human cells has thus
far been limited to lymphoblastoid and fibroblast cell
lines with variable results. For example, a recent study
that examined protein synthesis in a number of FXS
patient-derived cell lines found that only a subset of
these lines showed elevation in protein synthesis [14]. A
further examination of Fmr1KO mouse embryonic fibro-
blasts (MEFs) and neurons revealed that while there was
an overall increase in protein synthesis, the correlation
between matched MEFs and neurons was highly vari-
able, leading to the conclusion that the level of protein
synthesis in patient’s fibroblasts may not directly reflect
Fig. 4 Metformin normalizes the proliferation status of FMRP-deficient NPCs but does not improve the neurite deficit in FMRP-deficient neurons.
a Immunostaining shows proliferative markers BrdU (green) and Ki67 (red) expression. BrdU-labelling and Ki67 reveal increased proliferation in
FMR1KO compared to control in the vehicle-treated condition. Treatment with a range of doses of metformin (0.25, 0.5 and 1mM) ameliorates
the excessive proliferation rate in the FMR1KO NPCs. Scale bar = 50 μm. b Quantification of BrdU- and Ki67-positive cells by ImageJ. Values shown
as mean ± SEM based on blinded counting of 10 images per genotype per treatment condition. Statistical significance was determined by one-
way ANOVA with Fisher’s LSD post hoc test; *p < 0.05, **p < 0.01 and ***p < 0.001; number sign (#) for comparison to control-vehicle and dollar
sign ($) for comparison to KO-vehicle. c Neurite outgrowth and branching measurements for neurons treated with 0.5 or 1 mM metformin over
the course of 7 days. Values shown as mean ± SD from 4 independent wells of 9 image fields per genotype
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the protein synthesis in neurons. These results
highlighted the need for direct confirmation of protein
synthesis elevation in human FMRP-deficient neurons.
In our study, we showed for the first time that elevated
protein synthesis occurs in both human FMRP-deficient
neural progenitors and neurons.
Mechanistic studies in animal models have identified a
number of pathways contributing to elevated protein
synthesis in FXS. We evaluated the activation of two of
these pathways, namely the Akt/mTOR and MAPK/
ERK1/2 pathways. Variable results have been reported
with respect to their activation at baseline. Osterweil
and colleagues reported no increase in either ERK1/2 or
Akt activation in Fmr1KO brain slices in both basal and
DHPG-induced long-term depression (LTD), despite a
robust increase in protein synthesis [8, 21]. In contrast, a
study by Sharma and colleagues found increased Akt-
mTOR pathway activation in the Fmr1 KO hippocam-
pus, caused by elevated expression of the PI3K enhancer
protein PIKE [9]. In addition, increased level of phos-
phorylated ERK1/2 has been reported in the FXS human
post mortem brain [40]. In our study, we observed that
in both FXS isogenic hESC-derived NPCs and neurons,
phosphorylated Akt and ERK levels were aberrantly ele-
vated in parallel to excessive protein synthesis.
The ability to modulate protein synthesis pathways
along with a well-established safety and tolerability pro-
file have led to interest in metformin as a treatment for
FXS. Treatment with metformin was found to rescue a
number of FXS-associated deficits in Drosophila and
mouse models of FXS [23, 41]. Chronic and acute treat-
ment of metformin ameliorated olfactory learning and
long-term memory deficits in the dfmr1 mutants [41]. In
Fmr1KO, mice treatment with metformin for 10 days
rescued excessive translation, corrected various behav-
ioural deficits, and decreased audiogenic seizures [23].
Mechanistically, metformin was found to correct ele-
vated ERK, but not mTOR/Akt, signalling in Fmr1KO
mice [23]. These findings in FXS animal models formed
the basis for clinical trial of metformin as a treatment
for FXS. Preliminary reports from the early stages of
clinical trial in seven patients (6 adults and 1 child)
showed promising improvements in speech, irritability,
social behaviour and hyperactivity [42]. More recently, a
report from two adult patients that have been on met-
formin for 1 year described significant improvements in
cognitive and behaviours, as well as normalization of
weight and eating habits [43].
In this study, we show that metformin does indeed
normalize elevated protein synthesis in human FMRP-
deficient NPCs and neurons. We further demonstrate
that the improvements in neurodevelopmental abnor-
malities achieved were only partially, suggesting that ex-
cessive translation may not directly contribute to all
FXS-associated deficits and that metformin treatment is
likely to yield partial benefit.
In contrast to previous studies [23], the effect of met-
formin on protein synthesis was not dependent on
normalization of pERK1/2 levels. Metformin is known to
act through a number of pathways that converge on pro-
tein synthesis, such as the AMPK-dependent mTOR
pathway and the AMPK-independent Raf/MEK/ERK sig-
nalling pathways [44]. It has been shown that the nature
of the specific pathways activated by metformin depends
on the tissue/cell-type, dose, as well as the treatment
duration. Differences in one or more such parameters
likely account for our observations of rescued protein
synthesis in FMRP-deficient neural cells following met-
formin treatment despite the lack of effect on pERK1/2
levels.
Limitations
The limitations of the study include the need to delin-
eate in more detail the mechanism(s) by which metfor-
min normalizes protein synthesis in FMRP-deficient
human neurons, the assessment of the effect of metfor-
min on a broader range of phenotypic abnormalities, as
well as the concurrent assessment of the effect of met-
formin on protein synthesis and phenotypic deficits in
the same cell population.
Conclusion
In this study, we show that FMRP deficiency results in
increased de novo protein synthesis in human neural
cells as well as elevated ERK1/2 and Akt signalling. We
further show that treatment with metformin normalizes
in an Akt/ERK1/2-independent manner the elevation in
protein synthesis and rescues some, but not all, neurode-
velopmental abnormalities in FMRP-deficient neural
cells. Overall, our study validates metformin as a modu-
lator of protein synthesis in human neurons, suggests
that its therapeutic effects are likely to be partial, and
supports its further clinical development.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13229-020-00350-5.
Additional file 1: Figure S1. Assessment of FMRP expression in control
and FMR1KO ESC, NPC and neurons. The expression of FMRP was
assessed in ESC, NPCs and neurons by immunoblot. FMR1KO showed
absence of FMRP expression in all cell types. CON = control; KO =
FMR1KO. Figure S2. Assessment of de novo protein synthesis and
phosphorylation of ERK1/2 and Akt in FXS NPCs treated with 0.5 mM
metformin. (A) Protein synthesis (SUnSET assay) was performed in NPCs
treated with 0.5 mM metformin. A representative immunoblot image is
shown with 2 replicates per group. Relative expression of puromycin was
quantified by ImageJ and normalized to control-vehicle. Values shown as
mean ± SEM (n=4 per group). *p < 0.05 and **p < 0.01 by one-way
ANOVA with Fisher’s LSD post-hoc test. (B) Levels of phosphorylated Akt,
total Akt, phosphorylated ERK and total ERK in untreated and metformin-
Utami et al. Molecular Autism           (2020) 11:41 Page 9 of 11
treated NPCs were assessed by immunoblot. Values shown as mean ±
SEM (n=3 per group). *p < 0.05 by one-way ANOVA with Fisher’s LSD
post-hoc test. Figure S3. Assessment of de novo protein synthesis and
phosphorylation of ERK1/2 and Akt in FXS NPCs treated with 0.1 and 1
mM metformin (A) Protein synthesis (SUnSET assay) was performed in
NPCs treated with 0.1 and 1 mM metformin. A representative immuno-
blot image is shown. Relative expression of puromycin was quantified by
ImageJ and normalized to the control-vehicle. Values shown as mean ±
SEM from three replicates per genotype, from two immunoblot experi-
ments. * p < 0.05 as determined by one-way ANOVA with Tukey post-
hoc test. (B) Expression of phosphorylated Akt, total Akt, phosphorylated
ERK and total ERK for untreated and metformin-treated condition was
assessed by immunoblotting. A representative immunoblot image is
shown. Values shown as mean ± SEM (n=4 per group). *p < 0.05, as de-
termined by two-way ANOVA with Fisher’s LSD post-hoc test. Figure S4.
No effect of metformin treatment on control or FMR1KO NPC counts.
Total number of control and FMR1KO cells (based on DAPI-positive cells)
in NPCs cultures treated with vehicle or metformin (1 mM). There were
no significant differences among the groups and treatment conditions.
Values shown are based on 10 image fields per group and treatment
condition. Figure S5. Assessment of de novo protein synthesis and met-
formin effect on proliferation in FXS and control hiPSC-derived NPCs. (a)
Protein synthesis (SUnSET assay) was performed in 2 Control and 2 FXS
hiPSC-derived NPCs. Relative expression of puromycin was quantified by
ImageJ. Values shown as mean ± SEM from three replicates per geno-
type. *p < 0.05 and **p < 0.01 by one-way ANOVA with Fisher LSD post-
hoc test; (b) Immunostaining shows proliferative markers BrdU (Green)
and Ki67 (Red) expression. BrdU labelling and Ki67 reveals increased pro-
liferation in FXS iPSC-derived NPCs compared to control in the vehicle-
treated condition. Treatment with 0.5 mM metformin ameliorates the ex-
cessive proliferation rate in the FXS hiPSC-derived NPCs. Scale bar = 50
μm; (c) Quantification of BrdU- and Ki67-positive cells by ImageJ. Values
shown as mean ± SEM based on blinded counting of 8 images from
three coverslips per cell line.
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